Cyclosporine eye drops are among the most prescribed therapies for chronic dry eye disease. For many patients, however, commercial formulations do not fully address the clinical picture — whether because of concentration constraints, formulation tolerability, indication, or ocular surface complexity. This article offers a pharmacist-level clinical overview of cyclosporine ophthalmic therapy and the circumstances in which a compounded prescription from Town & Country Compounding Pharmacy may be the appropriate clinical choice.

What Are Cyclosporine Eye Drops?

Cyclosporine is a calcineurin inhibitor that modulates immune system activity by suppressing T-cell activation. When formulated as an ophthalmic emulsion or solution, it acts locally in the eye rather than systemically, targeting the inflammatory processes that underlie chronic dry eye disease (DED).

Commercially available cyclosporine ophthalmic products in the United States include formulations at 0.05%, 0.09%, and 0.1% concentrations — each with fixed concentration, fixed vehicle, and fixed preservative profile.

It is important to distinguish cyclosporine eye drops from standard artificial tears or lubricating drops. Lubricating drops address the symptom of inadequate tear film, while cyclosporine ophthalmic targets a root cause: chronic inflammation that impairs lacrimal gland function and ocular surface integrity. These are mechanistically different interventions; cyclosporine is an immunomodulatory agent, not a lubricant.

How Do Cyclosporine Eye Drops Work?

Cyclosporine inhibits calcineurin, a phosphatase involved in activating T-lymphocytes. In dry eye disease, T-cell infiltration of the lacrimal gland and conjunctival tissue drives chronic inflammation that progressively impairs tear secretion and damages the ocular surface. By suppressing this pathway locally, cyclosporine ophthalmic may reduce that inflammatory burden and support more functional tear film production.

One clinical reality to communicate to patients: cyclosporine eye drops do not provide immediate relief. Clinical studies have shown that the full therapeutic benefit may take three to six months of consistent twice-daily use to become apparent. Early discontinuation is common, and often premature — patients who stop in the first four to eight weeks may be abandoning a therapy that has not yet had time to work.

Consistent, uninterrupted use is essential to achieving the anti-inflammatory effect cyclosporine ophthalmic is designed to deliver.

Compounded Cyclosporine Eye Drops: Clinical Rationale and Prescribing Considerations

Compounded cyclosporine ophthalmic formulations are sterile preparations prepared by a licensed compounding pharmacy based on a valid prescription from a licensed healthcare provider. They are not manufactured products and are not FDA-approved as finished drug products; they are a prescription-required pharmaceutical option prepared to address specific patient needs that commercially available products do not meet.

The commercial products approved for dry eye disease are available only in fixed concentrations, fixed formulations (cationic emulsion or nanomicellar), and fixed preservative profiles. For many patients, these constraints are clinically limiting.

Why Compounded Cyclosporine Eye Drops May Be Necessary

The prescribing rationale for compounded cyclosporine ophthalmic almost always comes down to one core principle: the commercial product exists but does not meet this patient’s specific clinical need — whether that’s concentration, formulation, tolerability, or indication. That is the clinical rationale that supports the 503A compounding justification from a regulatory standpoint.

Specific clinical scenarios include:

Non-labeled indications requiring different concentrations: FDA-approved commercial products are indicated specifically for keratoconjunctivitis sicca. Prescribers using cyclosporine for other ocular surface diseases — corneal transplant rejection prophylaxis, vernal keratoconjunctivitis, chronic allergic conjunctivitis, superior limbic keratoconjunctivitis, meibomian gland dysfunction, or ocular pemphigoid — often require concentrations not commercially available.

Excipient intolerance: Some patients react to components of commercial formulations (castor oil, polysorbate 80, or other excipients). A compounded preparation can be made in an alternative vehicle — oil base or aqueous suspension — to improve tolerability.

Preservative sensitivity: Patients with severe ocular surface disease are frequently sensitive to benzalkonium chloride (BAK) and other preservatives. Town & Country Compounding Pharmacy can prepare preservative-free formulations in unit-dose or multi-dose formats tailored to those patients.

Formulation vehicle: Patients who experience significant burning with the emulsion-based commercial formulation may achieve better tolerability with an alternative vehicle, such as an aqueous suspension or oil-based solution.

Examples of Cyclosporine Eye Drop Formulation Options at Town & Country Compounding

Each formulation is prepared to USP <797> sterile compounding standards. Prescribers can contact our pharmacy directly to discuss clinical fit, concentration requirements, and formulation options for specific patient presentations.

More on Ophthalmic Compounding →

Sterile Compounding Standards at Town & Country Compounding Pharmacy

Ophthalmic preparations carry distinct sterility requirements. The eye is highly sensitive and directly connected to systemic circulation through the nasolacrimal system. Any breach in sterility in an ophthalmic preparation poses direct risk to the patient.

Compounded ophthalmic preparations must be prepared under USP <797> sterile compounding standards, which govern environmental controls, sterility testing, personnel qualifications, endotoxin limits, and beyond-use dating. Not all compounding pharmacies have the infrastructure, equipment, or accreditation to prepare sterile ophthalmic formulations to these standards.

Town & Country Compounding Pharmacy is a PCAB-accredited, 503A-licensed compounding pharmacy with dedicated sterile compounding capability operating under USP <797> standards. Our sterile ophthalmic preparations are prepared in cleanroom-classified environments in accordance with the regulatory requirements applicable to patient-specific 503A compounding.

Prescribers can review our full accreditations.

Partnering with Town & Country Compounding Pharmacy

Chronic dry eye disease is a long-term condition that often requires long-term therapy. When the standard commercial options create barriers — whether tolerability, formulation constraints, or off-label clinical need — compounded cyclosporine ophthalmic may be the appropriate next step in the clinical conversation.

Town & Country Compounding Pharmacy prepares sterile ophthalmic formulations for patients in our licensed states with a valid prescription from a licensed healthcare provider. Our compounding pharmacists work directly with prescribers to prepare patient-specific formulations that meet both clinical requirements and USP <797> sterile preparation standards.

If you’re a provider seeking a sterile compounding partner for ophthalmic preparations, we invite you to review our Specialties and accreditations. Partner with Us or visit the Provider Portal to learn more about ordering workflows and our formulary.

We ship to patients in all of our licensed states.

This article is for informational purposes only and does not constitute medical advice. Compounded medications are prepared by a licensed compounding pharmacy based on a valid prescription from a licensed healthcare provider. Compounded medications are not FDA-approved as finished drug products. Clinical appropriateness of any compounded formulation should be determined by the prescribing provider in consultation with the compounding pharmacist.